Gadolinium accumulation and fibrosis in the liver after administration of gadoxetate disodium in a rat model of active hepatic fibrosis

Radiology

Volumn 264, Issue 2, 2012, Pages 423-427

  Hope, Thomas A ^a   Doherty, Amanda ^a   Fu, Yanjun ^a   Aslam, Rizwan ^a   Qayyum, Aliya ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; CREATININE; ECHOVIST; GADOXETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG MEGADOSE; DRUG RETENTION; HISTOPATHOLOGY; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; RAT; STUDENT T TEST;

ANALYSIS OF VARIANCE; ANIMALS; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC;

EID: 84864355926     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112453     Document Type: Article

References (30)

1. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999;290(1):153-157. (Pubitemid 29302315)
2. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
3. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17(9):2359-2362. (Pubitemid 44300951)
4. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139(7):903-906. (Pubitemid 36898926)
5. Sanyal S, Marckmann P, Scherer S, Abraham JL. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis: an autopsy-based review. Nephrol Dial Transplant 2011;26(11):3616-3626.
6. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 2011;259(1):142-150.
7. Kato N, Takahashi M, Ihara S, Tsujimoto T, Miyazawa T. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis. Acad Radiol 1998;5(Suppl 1):S83-S85.
8. Mühler A, Weinmann HJ. Biodistribution and excretion of 153Gd-labeled gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid following repeated intravenous administration to rats. Acad Radiol 1995;2(4):313-318.
9. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOBDTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183(1):59-64.
10. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243(1):148-157. (Pubitemid 46579705)
11. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126(7):1795-1808. (Pubitemid 38736345)
12. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102(3):538-549. (Pubitemid 28376157)
13. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995;19(12):1409-1417.
14. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696-699.
15. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56(1):27-30. (Pubitemid 44969309)
16. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56(1):21-26. (Pubitemid 46017000)
17. Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2011;64(1):91-96.
18. Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis: a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009;61(6):537-552.
19. Clauss M, Sunderkötter C, Sveinbjörnsson B, et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 2001;97(5):1321-1329. (Pubitemid 32183755)
20. Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M. Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005;24(6):508-512.
21. Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi-gadoxetic acid-enhanced MR imaging. Radiology 2010;256(3):767-773.
22. Kojima H, Nies AT, König J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 2003;39(5):693-702. (Pubitemid 37372176)
23. Ogasawara K, Terada T, Katsura T, et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 2010;25(2):190-199.
24. Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001;21(4):247-253. (Pubitemid 32677380)
25. Planchamp C, Montet X, Frossard J-L, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 2005;40(4):187-194. (Pubitemid 40393229)
26. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991;22(2):233-237; discussion 242.
27. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195(3):785-792.
28. Döhr O, Hofmeister R, Treher M, Schweinfurth H. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 2007;42(12):830-841. (Pubitemid 350126565)
29. Schuhmann-Giampieri G, Mahler M, Röll G, Maibauer R, Schmitz S. Pharmacokinetics of the liver-specific contrast agent Gd-EOBDTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 1997;37(7):587-596. (Pubitemid 27443539)
30. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43(1):65-75.